Supernus Pharma and Indivior have signed an all-stock merger agreement that would establish a new company, focused on central nervous system (CNS) diseases, with combined revenues of around $2.2 billion. The combined company, to be known as Supernus Inc, would combine Indivior's treatments for opioid use disorder (OUD) with Supernus' portfolio of medicines for disorders like attention-deficit hyperactivity disorder (ADHD), depression, Parkinson's disease, epilepsy, and migraine, with 11 marketed products. As it stands, Indivior shareholders will own around 56.5% of the new company on closing, while Supernus' investors will have a 43.5% stake. Supernus Inc will be led by current Supernus Pharma chief executive Jack Khattar and maintain its Nasdaq listing under the SUPN ticker symbol. Supernus' current headquarters in Rockville, Maryland, will serve as the combined company's global headquarters.